BostonGene, a leader in AI-powered solutions for drug discovery and development, announced that six abstracts have been accepted at the 2025 ASCO Annual Meeting, scheduled for May 31 – June 3, 2025, at McCormick Place Convention Center in Chicago. The company will exhibit at booth #15147, showcasing its validated multimodal AI platform that combines deep molecular profiling, immune system characterization, and advanced analytics to accelerate oncology drug development.
Advancing Precision Oncology Through AI-Driven Research
The six accepted studies, conducted independently and in collaboration with leading academic institutions, demonstrate how BostonGene's platform uncovers novel biomarkers, refines patient stratification, and predicts therapeutic response across a range of tumor types. The presentations will highlight advancements in transcriptomic analysis, immune microenvironment profiling, histomolecular subtyping, and blood-based predictors—key tools for improving clinical trial design and driving precision treatment strategies.
Sarcoma Molecular Subtyping and Prognosis
In Abstract 11536, titled "Molecular subtyping and insights into sarcoma biology and prognosis," BostonGene's multiomic Tumor Portrait™ test was used to identify distinct molecular patterns in various sarcoma subtypes that correlated with survival outcomes. The study, presented by Nikita Kotlov from BostonGene, demonstrates the potential clinical impact of advanced analytics paired with molecular sequencing in diverse diseases such as sarcoma.
Breast Cancer Subtype Analysis
Abstract 1049, "Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes," represents a collaboration with MD Anderson Cancer Center. Jason Mouabbi, MD, from The University of Texas MD Anderson Cancer Center, will present findings where BostonGene's advanced analytic platform identified unique histologic and molecular findings in invasive lobular carcinoma (ILC), a subtype of breast cancer for which treatment options are often inferred. Profiling of over 600 patients resulted in the discovery of biologic mechanisms and alterations that could direct future therapeutic and drug development strategies.
Liposarcoma Gene Fusion Discovery
In Abstract 11561, "Detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing," BostonGene leveraged its extensive internal cohort and advanced sequencing technologies to conduct transcriptome analysis of Liposarcoma (LPS) samples. The study, presented by Lev Bedniagin, MD, from BostonGene, revealed novel hotspots of gene fusions in LPS patients. These discoveries can be used to improve diagnostic accuracy and the development of novel therapeutics in LPS and similar diseases.
Cancer of Unknown Primary Characterization
Abstract 4198, "Uncovering the Tumor Microenvironment (TME): Exploring survival and immunotherapy (IO) response in Cancer of Unknown Primary (CUP)," represents another collaboration with MD Anderson Cancer Center. Joelle Allam, MD, from The Texas University MD Anderson Cancer Center, will present how BostonGene utilized its Tumor Portrait™ test to characterize Cancer of Unknown Primary (CUP). The analysis revealed correlations of clinical factors, the tumor microenvironment, and immunotherapy response with survival outcomes, offering new insights into this challenging and poorly defined cancer.
Lung Cancer Biomarker Identification
In Abstract 2634, "Tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer," BostonGene leveraged its AI-driven Kassandra deconvolution algorithm to analyze transcriptomic data from patients with non-small cell lung cancer. The study, presented by Lev Bedniagin, MD, identified unique tertiary lymphoid structures within the tumor microenvironment that may serve as predictive and prognostic biomarkers, enhancing the efficacy of immune checkpoint inhibitor therapy.
Prostate Cancer Treatment Guidance
An online-only presentation titled "The impact of PTEN deletion, TMPRSS2:ERG fusion, and androgen receptor variant 7 (AR-V7) on resistance to novel hormone therapies (NHTs) in castrate-resistant prostate cancer" demonstrated the clinical utility of the BostonGene Tumor Portrait™ test in guiding treatment selection for castrate-resistant prostate cancer based on tumor microenvironment-related gene signatures. These findings underscore the importance of precision medicine in managing cancer subtypes that are resistant to traditional interventions.
Platform Capabilities and Clinical Impact
BostonGene's multimodal AI platform integrates advanced molecular and immune profiling with clinical data to uncover actionable insights that inform trial design, optimize patient selection, and improve clinical outcomes. The company's diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients, supported by a CLIA-certified and CAP-accredited clinical laboratory.
The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings, providing broader access to these research findings for the oncology community.
